Update on the endocannabinoid system as an anticancer target

Area of Science:

• Oncology
• Pharmacology
• Endocannabinoid System Research

Background:

• The endocannabinoid system (ECS) is increasingly recognized as a potential target for cancer therapy.
• The ECS, comprising cannabinoid receptors, endogenous ligands, and enzymes, plays a role in cancer cell proliferation.
• Existing research indicates the ECS involvement in both in vitro and in vivo cancer growth models.

Purpose of the Study:

• To review the literature from the past decade on targeting the ECS for cancer treatment.
• To discuss the expression of endocannabinoids and their receptors in various cancers.
• To explore signaling pathways and therapeutic compounds related to ECS-driven antitumor effects.

Main Methods:

• Literature review of studies published in the last 10 years.
• Analysis of endocannabinoid levels and receptor expression in different cancer types.
• Evaluation of signaling pathways implicated in antitumor effects.
• Assessment of clinical data on existing and novel compounds.

Main Results:

• The ECS demonstrates significant involvement in cancer cell growth.
• Specific endocannabinoids and receptor expression patterns are associated with various cancers.
• Signaling pathways influenced by the ECS contribute to antitumor effects.
• Various compounds targeting the ECS show potential therapeutic benefits and associated side effects.

Conclusions:

• Future antitumor therapies should prioritize compounds with lower psychoactivity, potentially by targeting the CB2 receptor or non-psychoactive CB1 ligands.
• Agents that activate cannabinoid receptors or inhibit enzymes like fatty acid amide hydrolase may impact tumor growth.
• Further research is needed on downstream effects of ECS modulation to identify additional therapeutic targets.